Protea Inks Cancer Analysis Alliance with MSKCC, Dana-Farber | GenomeWeb

NEW YORK (GenomeWeb) – Protea Biosciences Group said today that it has undertaken a collaborative research effort with Memorial Sloan Kettering Cancer Center and the Dana-Farber Cancer Institute with an initial focus on lung cancer.

The partners will use Protea's next generation LAESI (Laser Ablation Electrospray Ionization) direct molecular imaging technology to analyze cancer cells. Protea said they will "generate molecular data profiles of cancer cells in tissue and biofluids to improve the understanding of a cancer's origin."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.